Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > COVID-19’s impact on hospital services | CIHI
View:
Post by ScienceFirst on Dec 29, 2021 1:33pm

COVID-19’s impact on hospital services | CIHI

All Ph. 2b canadian sites (public healthcare hospitals) are doing elective surgeries as we speak.  US counterpart sites, though private clinics, have probably similar COVID-19 contamination issues, though maybe at lesser or more manageable level, but that would have to be demonstrated.

So in the late February newsletter, reality check, it's fair to assume that we'll probably have 50% of the results that we were initially expecting from patients at the moment of the previous newsletter (Nov. 29), as we enter into a more intense window of COVID-19 cases over the next 30-45-60 days, depending on how all this unfolds.

The COVID-19 cases puts a huge burden on hospitals budgets.  Huge.  We've never seen anything like that over the last 80 years and Omicron numbers outpace Delta numbers in terms of volume, despite better protection, better vaccines.

COVID-19’s impact on hospital services | CIHI
Comment by fredgoodwinson on Dec 29, 2021 1:46pm
Hi Science First - are you saying that we might end up with patients in a Clinical Trial not being monitored when their milestones (which wait for no man) are due?
Comment by ScienceFirst on Dec 29, 2021 2:21pm
Fred ... That's what is fair to consider, considering the current situation.   Expecting business as usual would not be logic.  I would lower my expectation a bit.  
Comment by fredgoodwinson on Dec 29, 2021 3:01pm
While it is possible that enrollment might be affected highly doubt that the Clinical Protocol will be altered for existing participants and could well have enough to get us over the line for BTD with them alone.
Comment by Longholder99 on Dec 29, 2021 5:47pm
Ya Im thinking that the pandemic is behind much of the general delays in enrollment vis a vis provedures being halted to make beds available...yet here we are. At tye doorstep of BTD. Not worried as I believe the FDA probably still sees cancer as a worthy malady in the face of the covid drama going on everywhere.
Comment by ScienceFirst on Jan 03, 2022 1:21pm
Doug Ford is currently announcing in a press conference that all elective surgeries are cancelled, due to the burden that COVID-19 is putting on the healthcare system.  So it implies our Ph. 2b Ontario sites. So it's fair to assume that other places will have the same tough decision to make.  Like Quebec (McGill site), etc ...  So it could possibly delay some cystoscopies that ...more  
Comment by ScienceFirst on Jan 03, 2022 1:23pm
Ontario Premier Doug Ford announced a host of new public health measures Monday, nearly three weeks after the province's science table warned that the Omicron variant could threaten the stability of the health-care system.
Comment by ScienceFirst on Jan 03, 2022 1:25pm
Ontario is moving schools online for at least two weeks, temporarily closing indoor dining and gyms and pausing non-urgent medical procedures as it faces record-high case counts that, according to public health officials, threaten to overwhelm the province's health-care system. Premier Doug Ford announced the changes at a morning news conference Monday. He was joined by his ...more  
Comment by thadeush on Jan 03, 2022 1:34pm
It'$ a ri$k he ab$olutely took to $ave money and promote private $olution$. He KNEW 3 week$ ago about the danger$ of Omicron, but it took him "30 $econd$" to make the decision today AFTER he realized the massive public outcry against his complete incompetence and inaction will affect his ELECTION re$ults. (Sorry for the sort-of (but not really) off-topic post)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250